Summary:
- The article provides a critical analysis of the clinical trial data surrounding Pelacarsen, an antisense oligonucleotide designed to lower Lipoprotein(a) levels to reduce cardiovascular risk.
- It examines the potential disconnect between the surrogate endpoint of reducing Lipoprotein(a) and the clinical reality of whether this intervention effectively prevents major adverse cardiovascular events (MACE).
- The author challenges the prevailing scientific enthusiasm for the drug by scrutinizing the methodology and the long-term prognostic implications of the ongoing HORIZON trial.